Market Closed -
Nasdaq
04:15:00 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
42.75
USD
|
-1.04%
|
|
-3.37%
|
-10.60%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,467
|
9,158
|
5,732
|
3,248
|
3,926
|
3,551
|
-
|
-
|
Enterprise Value (EV)
1 |
1,712
|
7,956
|
4,992
|
2,500
|
3,149
|
3,278
|
3,214
|
3,206
|
P/E ratio
|
-6
x
|
-45.1
x
|
-12.6
x
|
-4.58
x
|
-5.8
x
|
-6.51
x
|
-8.18
x
|
-12.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
23.8
x
|
33.8
x
|
16.3
x
|
8.94
x
|
9.04
x
|
6.94
x
|
5.67
x
|
4.08
x
|
EV / Revenue
|
16.5
x
|
29.4
x
|
14.2
x
|
6.88
x
|
7.25
x
|
6.4
x
|
5.13
x
|
3.68
x
|
EV / EBITDA
|
-4.12
x
|
-25
x
|
-13.5
x
|
-3.96
x
|
-5.8
x
|
-6.86
x
|
-7.76
x
|
-15.6
x
|
EV / FCF
|
-4.62
x
|
-45.2
x
|
-12.1
x
|
-5.03
x
|
-6.07
x
|
-7.21
x
|
-10
x
|
-15.8
x
|
FCF Yield
|
-21.6%
|
-2.21%
|
-8.25%
|
-19.9%
|
-16.5%
|
-13.9%
|
-9.98%
|
-6.31%
|
Price to Book
|
3.78
x
|
7.3
x
|
6.32
x
|
9.23
x
|
12.8
x
|
7.59
x
|
4.28
x
|
4.4
x
|
Nbr of stocks (in thousands)
|
57,771
|
66,156
|
68,162
|
70,106
|
82,106
|
83,070
|
-
|
-
|
Reference price
2 |
42.71
|
138.4
|
84.09
|
46.33
|
47.82
|
42.75
|
42.75
|
42.75
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/10/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
103.7
|
271
|
351.4
|
363.3
|
434.2
|
511.7
|
626.9
|
870.1
|
EBITDA
1 |
-415.6
|
-317.9
|
-368.5
|
-630.7
|
-543.2
|
-477.5
|
-414.1
|
-205.2
|
EBIT
1 |
-424.2
|
-330.1
|
-381.7
|
-648.9
|
-569.2
|
-531.4
|
-451.3
|
-294.7
|
Operating Margin
|
-408.98%
|
-121.8%
|
-108.63%
|
-178.6%
|
-131.08%
|
-103.83%
|
-71.99%
|
-33.87%
|
Earnings before Tax (EBT)
1 |
-399.4
|
-185.4
|
-453
|
-701.7
|
-608.5
|
-557.8
|
-478.1
|
-319.9
|
Net income
1 |
-402.7
|
-186.6
|
-454
|
-707.4
|
-606.6
|
-559.6
|
-475.6
|
-329.5
|
Net margin
|
-388.31%
|
-68.84%
|
-129.2%
|
-194.71%
|
-139.7%
|
-109.36%
|
-75.86%
|
-37.87%
|
EPS
2 |
-7.120
|
-3.070
|
-6.700
|
-10.12
|
-8.250
|
-6.567
|
-5.228
|
-3.415
|
Free Cash Flow
1 |
-370.2
|
-176.1
|
-411.8
|
-496.6
|
-519.1
|
-454.6
|
-320.9
|
-202.4
|
FCF margin
|
-356.96%
|
-64.98%
|
-117.18%
|
-136.68%
|
-119.53%
|
-88.83%
|
-51.19%
|
-23.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/10/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
83.39
|
79.94
|
89.34
|
90.7
|
103.3
|
100.5
|
108.3
|
98.05
|
127.4
|
108.8
|
123
|
131.7
|
146.9
|
137.7
|
148.6
|
EBITDA
1 |
-99.03
|
-
|
-137.1
|
-220.4
|
-140.7
|
-148.9
|
-142.6
|
-137.9
|
-113.8
|
-
|
-105.6
|
-90.82
|
-62.34
|
-
|
-
|
EBIT
1 |
-102.6
|
-136.6
|
-141.6
|
-225.1
|
-145.6
|
-154.1
|
-148
|
-145.1
|
-122
|
-165.3
|
-135.1
|
-124.6
|
-110.9
|
-127.5
|
-120.3
|
Operating Margin
|
-122.99%
|
-170.93%
|
-158.48%
|
-248.14%
|
-140.91%
|
-153.34%
|
-136.61%
|
-147.98%
|
-95.81%
|
-151.93%
|
-109.9%
|
-94.62%
|
-75.51%
|
-92.57%
|
-80.95%
|
Earnings before Tax (EBT)
1 |
-122.4
|
-151.8
|
-157.9
|
-238.8
|
-153.3
|
-163.5
|
-159.1
|
-159
|
-126.9
|
-170.2
|
-140.4
|
-130.3
|
-117.3
|
-134.3
|
-127.1
|
Net income
1 |
-122.5
|
-152.3
|
-158.2
|
-245.1
|
-151.8
|
-164
|
-159.8
|
-159.6
|
-123.2
|
-170.7
|
-140.6
|
-131
|
-117.4
|
-134.4
|
-127.2
|
Net margin
|
-146.85%
|
-190.55%
|
-177.03%
|
-270.23%
|
-146.91%
|
-163.16%
|
-147.57%
|
-162.82%
|
-96.7%
|
-156.83%
|
-114.32%
|
-99.46%
|
-79.93%
|
-97.58%
|
-85.6%
|
EPS
2 |
-1.790
|
-2.190
|
-2.260
|
-3.500
|
-2.160
|
-2.330
|
-2.250
|
-2.230
|
-1.520
|
-2.030
|
-1.678
|
-1.537
|
-1.353
|
-1.397
|
-1.292
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/22
|
5/5/22
|
7/28/22
|
11/2/22
|
2/16/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/15/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
755
|
1,202
|
740
|
748
|
777
|
274
|
337
|
345
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-370
|
-176
|
-412
|
-497
|
-519
|
-455
|
-321
|
-202
|
ROE (net income / shareholders' equity)
|
-63.8%
|
-20.6%
|
-43.7%
|
-111%
|
-193%
|
-146%
|
-66.4%
|
-38.5%
|
ROA (Net income/ Total Assets)
|
-43.4%
|
-12.9%
|
-27.7%
|
-46.1%
|
-40%
|
-39.2%
|
-35.4%
|
-31.2%
|
Assets
1 |
927.5
|
1,447
|
1,641
|
1,534
|
1,518
|
1,428
|
1,345
|
1,055
|
Book Value Per Share
2 |
11.30
|
19.00
|
13.30
|
5.020
|
3.740
|
5.630
|
10.00
|
9.730
|
Cash Flow per Share
2 |
-6.100
|
-2.170
|
-4.940
|
-5.440
|
-6.460
|
-4.930
|
-3.550
|
-
|
Capex
1 |
24.8
|
43.9
|
73.1
|
116
|
44.3
|
20.3
|
40.5
|
43.3
|
Capex / Sales
|
23.94%
|
16.2%
|
20.8%
|
31.96%
|
10.19%
|
3.96%
|
6.45%
|
4.97%
|
Announcement Date
|
2/13/20
|
2/11/21
|
2/10/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
42.75
USD Average target price
89
USD Spread / Average Target +108.19% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.60% | 3.55B | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|